Back to search
FDAFDA · Food and drugs·Recall number D-0945-2023

FentaNYL 500 mcg/250 mL - Bupivacaine HCl 0.1% in 0.9% Sodium Chloride 250mL Bag, Injection for Epidural Use (fentaNYL Concentration - 2 mcg/mL), Rx Only, Single Dose Container, SCA Pharmaceuticals, 755 Rainbow Rd, Windsor, CT 06095, NDC# 70004-0253-40

Published August 2, 2023 · Recall initiated: July 20, 2023

Summary

FDA records drug Class II recall D-0945-2023, published August 2, 2023 and initiated July 20, 2023. Recalling firm: SCA Pharmaceuticals; Status: Terminated; Reported quantity: 183 bags; Lot: Lot # 1223047134, Use By: 09/21/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations: due to shipment of rejected units.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
SCA Pharmaceuticals
Distributor
KY and NJ
Lot
Lot # 1223047134, Use By: 09/21/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was FentaNYL 500 mcg/250 mL - Bupivacaine HCl 0.1% in 0.9% Sodium Chloride 250mL Bag, Injection for Epidural Use (fentaNYL Concentration - 2 mcg/mL), Rx Only, Single Dose Container, SCA Pharmaceuticals, 755 Rainbow Rd, Windsor, CT 06095, NDC# 70004-0253-40 recalled?

Yes. FDA published recall D-0945-2023 on August 2, 2023. Reported hazard: cGMP deviations: due to shipment of rejected units.

What should I do if I have this product?

Voluntary: Firm initiated · Letter